Tetanus toxoid-specific antibodies and T-cell receptors

Tetanus toxoid-specific antibodies and T-cell receptors (TCRs) are the primary molecular components of the adaptive immune response that recognize and respond to the tetanus toxin produced by Clostridium tetani (StatPearls, 2023). These receptors are elicited through vaccination with tetanus toxoid, a formal-inactivated version of the tetanospasmin neurotoxin (CDC, 2022). Antibodies, primarily of the IgG class, function by binding to the C-fragment of the toxin, thereby neutralizing its ability to attach to gangliosides on peripheral nerve terminals and preventing retrograde axonal transport to the central nervous system (PubMed, PMID: 10924236). T-cell receptors on CD4+ helper T cells recognize processed toxoid peptides presented by MHC class II molecules, which is essential for B-cell activation, isotype switching, and the establishment of long-term immunological memory (Journal of Immunology, 2018). In clinical practice, these immune components are used as benchmarks for assessing immunocompetence and vaccine efficacy. They also serve as model systems in the development of novel immunotherapy platforms, such as CAR-T cells and modular vaccine carriers (Nature Communications, 2021). Passive immunization using Tetanus Immune Globulin (TIG) provides immediate protection by supplying pre-formed antibodies to neutralize the toxin in non-immunized individuals (StatPearls, 2023). Monitoring the levels of these antibodies is the standard method for determining protective immunity in populations (WHO, 2018).

Other names

Anti-tetanus antibodiesTetanus-specific T-cell receptorsTT-specific immune receptorsAnti-tetanospasmin antibodiesTetanus-specific lymphocytes

Tetanus toxoid-specific antibodies neutralize the tetanus neurotoxin by blocking its binding to neuronal gangliosides, while T-cell receptors recognize toxoid peptides to coordinate B-cell activation and long-term immunity (StatPearls, 2023; PubMed, PMID: 10924236).